Clinic
UPMC Hamot
UPMC Hamot was paid $18.06M by Medicaid between Jan 2018 and Dec 2024, across 334 billing codes. Its largest line is 99284, emergency room visit (serious) — 29% of everything it billed.
33Billing provider infoUPMC HAMOT
ERIE, PA 16550
ERIE, PA 16550
33aNPI1487647590assigned 08/24/2005
33bProvider typeClinic/Center
28Total paid$18.06M
24GClaims631,335
24DCodes billed334
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinic/Center providers in Pennsylvania
Rank by total paid#10 of 176
Median peer was paid$441K
This provider vs. median41×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 305 | $28K | |
| 2019 | 1,203 | $33K | |
| 2020 | 62,186 | $1.58M | |
| 2021 | 247,331 | $8.04M | |
| 2022 | 110,637 | $3.11M | |
| 2023 | 119,217 | $2.92M | |
| 2024incomplete | 90,456 | $2.35M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 29% | 45,972 | 44,167 | $5.29M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 27,509 | 26,582 | $2.17M |
| G0378 | Hospital observation service, per hour | 9.6% | 5,487 | 2,321 | $1.72M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.8% | 10,266 | 9,770 | $1.40M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.4% | 5,151 | 5,079 | $438K |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 2.3% | 14,397 | 12,109 | $413K |
| G0299 | Direct skilled nursing services of a registered nurse (rn) in the home health or hospice setting, each 15 minutes | 2.1% | 3,428 | 983 | $382K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.9% | 15,467 | 14,478 | $340K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.8% | 43,893 | 39,643 | $331K |
| J9271 | Injection, pembrolizumab, 1 mg | 1.6% | 395 | 324 | $291K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 55,058 | 48,972 | $261K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.2% | 1,735 | 1,682 | $222K |
322 more codes
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.2% | 2,632 | $208K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.0% | 23,010 | $182K |
| G0151 | Services performed by a qualified physical therapist in the home health or hospice setting, each 15 minutes | <1% | 1,455 | $162K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,958 | $155K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 669 | $136K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,067 | $130K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 502 | $103K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 412 | $99K |
| 80053 | Comprehensive metabolic panel | <1% | 9,703 | $98K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,245 | $95K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,463 | $94K |
| 88342 | <1% | 2,279 | $90K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,376 | $89K |
| J3490 | Unclassified drugs | <1% | 10,769 | $87K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 523 | $82K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,845 | $79K |
| 99502 | <1% | 818 | $79K | |
| 80076 | <1% | 10,986 | $77K | |
| 84484 | <1% | 11,260 | $73K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,274 | $71K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 833 | $70K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 535 | $68K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 286 | $62K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,145 | $59K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,621 | $59K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,220 | $57K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,598 | $56K |
| 72141 | <1% | 254 | $56K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,041 | $55K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 376 | $51K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,446 | $47K |
| 95811 | <1% | 106 | $44K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 903 | $44K |
| 71045 | Radiologic examination, chest; single view | <1% | 7,979 | $43K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,062 | $43K |
| 93971 | <1% | 802 | $42K | |
| 59025 | Fetal non-stress test | <1% | 1,126 | $39K |
| G0152 | Services performed by a qualified occupational therapist in the home health or hospice setting, each 15 minutes | <1% | 323 | $36K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,645 | $35K |
| 99501 | <1% | 315 | $35K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,332 | $35K |
| 76536 | <1% | 752 | $33K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 88 | $33K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 150 | $33K |
| 83690 | <1% | 8,451 | $32K | |
| 73221 | <1% | 138 | $31K | |
| 77066 | Tomosynthesis, mammo | <1% | 364 | $28K |
| 70498 | <1% | 265 | $28K | |
| 70496 | <1% | 267 | $28K | |
| 81001 | <1% | 10,106 | $26K | |
| 76642 | <1% | 642 | $26K | |
| 93970 | <1% | 334 | $25K | |
| 96367 | <1% | 1,142 | $25K | |
| 71250 | <1% | 439 | $25K | |
| 73630 | <1% | 2,458 | $24K | |
| 82728 | <1% | 2,284 | $24K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 2,976 | $24K |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 198 | $23K |
| 76830 | Ultrasound, transvaginal | <1% | 555 | $23K |
| 78264 | <1% | 257 | $21K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,531 | $21K |
| 70486 | <1% | 367 | $21K | |
| 77065 | Tomosynthesis, mammo | <1% | 340 | $20K |
| 81025 | <1% | 6,292 | $20K | |
| 93976 | <1% | 302 | $20K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 405 | $19K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 685 | $19K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 833 | $18K |
| 87088 | <1% | 2,896 | $18K | |
| 74178 | <1% | 90 | $18K | |
| 72100 | <1% | 887 | $17K | |
| 88341 | <1% | 306 | $17K | |
| 76801 | <1% | 493 | $17K | |
| 93017 | <1% | 539 | $17K | |
| 93880 | <1% | 269 | $17K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 277 | $17K |
| 76770 | <1% | 356 | $16K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 179 | $16K |
| 96417 | <1% | 348 | $16K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 823 | $16K |
| 81003 | <1% | 6,898 | $15K | |
| 83540 | <1% | 2,018 | $15K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 782 | $15K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,577 | $14K |
| 73610 | <1% | 898 | $14K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 333 | $14K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 304 | $14K |
| 93226 | <1% | 401 | $13K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 151 | $13K |
| 94729 | <1% | 518 | $12K | |
| 76870 | <1% | 283 | $12K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 792 | $12K |
| 76775 | <1% | 287 | $11K | |
| 83735 | <1% | 2,745 | $11K | |
| 80050 | General health panel | <1% | 228 | $11K |
| 96415 | <1% | 315 | $11K | |
| 93923 | <1% | 293 | $11K | |
| 94726 | <1% | 473 | $10K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 600 | $10K |
| 92587 | <1% | 323 | $9K | |
| 73564 | <1% | 583 | $9K | |
| 84702 | <1% | 652 | $9K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 276 | $9K |
| 83550 | <1% | 1,990 | $9K | |
| 58558 | <1% | 12 | $9K | |
| 73030 | <1% | 711 | $9K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 1,778 | $9K |
| 73502 | <1% | 483 | $8K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 756 | $8K |
| 72156 | <1% | 39 | $8K | |
| 78227 | <1% | 24 | $8K | |
| 90715 | <1% | 1,075 | $7K | |
| 83615 | <1% | 1,171 | $7K | |
| 73130 | <1% | 743 | $7K | |
| 72050 | <1% | 287 | $7K | |
| 74018 | <1% | 651 | $7K | |
| 83880 | <1% | 505 | $7K | |
| 87040 | <1% | 788 | $7K | |
| 93225 | <1% | 414 | $6K | |
| 88313 | <1% | 208 | $6K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 15,038 | $6K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 11,143 | $6K |
| 73560 | <1% | 422 | $6K | |
| 87077 | <1% | 1,140 | $6K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 15 | $6K |
| 96523 | <1% | 419 | $5K | |
| 88360 | <1% | 107 | $5K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 173 | $5K |
| 80061 | Lipid panel | <1% | 563 | $5K |
| 85730 | <1% | 1,445 | $5K | |
| 73110 | <1% | 514 | $5K | |
| J1815 | Injection, insulin, per 5 units | <1% | 642 | $5K |
| G0300 | Direct skilled nursing services of a licensed practical nurse (lpn) in the home health or hospice setting, each 15 minutes | <1% | 42 | $5K |
| 87186 | <1% | 890 | $5K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 194 | $5K |
| 85610 | <1% | 2,457 | $5K | |
| 92567 | <1% | 373 | $4K | |
| 86850 | <1% | 1,007 | $4K | |
| 87210 | <1% | 884 | $4K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 243 | $4K |
| 43248 | <1% | 12 | $4K | |
| 84439 | <1% | 638 | $4K | |
| 73590 | <1% | 304 | $4K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,612 | $4K |
| 43235 | <1% | 27 | $4K | |
| 74183 | <1% | 13 | $4K | |
| 87631 | <1% | 13 | $4K | |
| 84703 | <1% | 461 | $4K | |
| C9399 | Unclassified drugs or biologicals | <1% | 404 | $4K |
| 85027 | <1% | 1,332 | $3K | |
| 83605 | <1% | 829 | $3K | |
| P9045 | Infusion, albumin (human), 5%, 250 ml | <1% | 218 | $3K |
| 70491 | <1% | 49 | $3K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 505 | $3K |
| 72070 | <1% | 173 | $3K | |
| 73090 | <1% | 302 | $3K | |
| 72040 | <1% | 182 | $3K | |
| 86920 | <1% | 137 | $3K | |
| 88312 | <1% | 43 | $3K | |
| 82784 | <1% | 173 | $3K | |
| 86901 | <1% | 1,142 | $3K | |
| 82977 | <1% | 269 | $3K | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 374 | $3K |
| 86900 | <1% | 1,114 | $3K | |
| 88304 | <1% | 547 | $2K | |
| 95819 | <1% | 229 | $2K | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 1,399 | $2K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 235 | $2K |
| 82570 | <1% | 398 | $2K | |
| 73700 | <1% | 41 | $2K | |
| 85378 | <1% | 377 | $2K | |
| 73080 | <1% | 267 | $2K | |
| 72110 | <1% | 116 | $2K | |
| 80329 | <1% | 255 | $2K | |
| 94060 | <1% | 263 | $2K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 24 | $2K |
| 94010 | <1% | 317 | $2K | |
| 71271 | <1% | 29 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 553 | $2K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,050 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,679 | $2K |
| 88307 | <1% | 344 | $2K | |
| 92552 | <1% | 206 | $2K | |
| 36430 | <1% | 51 | $2K | |
| 88344 | <1% | 30 | $2K | |
| 72158 | <1% | 15 | $2K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 20 | $2K |
| 97597 | <1% | 105 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,942 | $1K |
| 86140 | <1% | 625 | $1K | |
| 84100 | <1% | 324 | $1K | |
| J7999 | Compounded drug, not otherwise classified | <1% | 1,783 | $1K |
| 84550 | <1% | 268 | $1K | |
| 85652 | <1% | 553 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 800 | $1K |
| 88112 | <1% | 56 | $1K | |
| P9021 | Red blood cells, each unit | <1% | 28 | $1K |
| 84156 | <1% | 363 | $1K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,206 | $1K |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 70 | $1K |
| 73562 | <1% | 84 | $1K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,328 | $1K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16,663 | $1K |
| 73060 | <1% | 135 | $1K | |
| 92555 | <1% | 158 | $1K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 230 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,815 | $1K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,699 | $1K |
| 87070 | <1% | 288 | $1K | |
| 82803 | <1% | 77 | $991.32 | |
| 84460 | <1% | 169 | $931.59 | |
| 97165 | <1% | 160 | $881.63 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 163 | $872.23 |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 12 | $817.93 |
| 72131 | <1% | 13 | $817.26 | |
| 76882 | <1% | 135 | $807.08 | |
| 85046 | <1% | 131 | $800.11 | |
| 82565 | <1% | 243 | $785.10 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 128 | $773.57 |
| 77080 | <1% | 12 | $733.57 | |
| C1769 | Guide wire | <1% | 138 | $658.64 |
| 82607 | <1% | 77 | $657.43 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 435 | $654.07 |
| 80069 | <1% | 120 | $647.63 | |
| 96411 | <1% | 15 | $644.06 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,996 | $615.95 |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 27 | $614.43 |
| 97162 | <1% | 95 | $605.61 | |
| 84134 | <1% | 48 | $583.49 | |
| 94644 | <1% | 30 | $576.42 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 586 | $576.37 |
| 87205 | <1% | 292 | $575.77 | |
| 82150 | <1% | 157 | $565.78 | |
| 73552 | <1% | 43 | $559.72 | |
| 84450 | <1% | 111 | $553.23 | |
| 82550 | <1% | 150 | $537.23 | |
| 86618 | <1% | 28 | $509.80 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,826 | $496.56 |
| 82248 | <1% | 107 | $496.27 | |
| 71101 | <1% | 40 | $488.78 | |
| 83970 | <1% | 12 | $480.86 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,147 | $477.83 |
| 92611 | <1% | 12 | $463.73 | |
| 93922 | <1% | 14 | $450.04 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,421 | $449.36 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,185 | $406.28 |
| 73620 | <1% | 60 | $381.55 | |
| 87081 | <1% | 108 | $349.21 | |
| 95816 | <1% | 31 | $346.91 | |
| 82009 | <1% | 101 | $331.64 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,684 | $324.45 |
| 87430 | <1% | 40 | $324.28 | |
| 74022 | <1% | 13 | $306.16 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 27 | $303.30 |
| 85007 | <1% | 74 | $298.86 | |
| 72170 | <1% | 53 | $295.76 | |
| 85384 | <1% | 32 | $291.22 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 12 | $287.86 |
| 74220 | <1% | 13 | $274.50 | |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 57 | $267.54 |
| S0028 | Injection, famotidine, 20 mg | <1% | 309 | $258.12 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 47 | $241.08 |
| 82962 | <1% | 171 | $239.38 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 388 | $239.01 |
| 85347 | <1% | 44 | $232.87 | |
| 73600 | <1% | 26 | $214.92 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 302 | $214.10 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 674 | $210.89 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,487 | $206.23 |
| Q9956 | Injection, octafluoropropane microspheres, per ml | <1% | 17 | $205.53 |
| 85576 | <1% | 15 | $182.55 | |
| 82140 | <1% | 95 | $175.02 | |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 13 | $167.62 |
| 99152 | <1% | 41 | $153.81 | |
| 96376 | <1% | 533 | $153.37 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 287 | $149.44 |
| 96368 | <1% | 15 | $143.02 | |
| 84520 | <1% | 57 | $131.61 | |
| 73140 | <1% | 13 | $123.36 | |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 774 | $117.34 |
| J0280 | Injection, aminophyllin, up to 250 mg | <1% | 92 | $116.14 |
| 86592 | <1% | 43 | $112.54 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 942 | $109.65 |
| 76937 | <1% | 54 | $105.75 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 265 | $102.42 |
| 73120 | <1% | 13 | $100.69 | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,356 | $95.88 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 28 | $93.29 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 219 | $80.82 |
| 82247 | <1% | 14 | $78.50 | |
| 82043 | <1% | 12 | $75.48 | |
| 85651 | <1% | 33 | $72.98 | |
| 88302 | <1% | 13 | $69.45 | |
| 85014 | <1% | 55 | $66.81 | |
| 77001 | <1% | 16 | $65.38 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 257 | $64.91 |
| 36600 | <1% | 15 | $62.07 | |
| 82330 | <1% | 14 | $61.22 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 182 | $61.16 |
| 85018 | <1% | 38 | $57.13 | |
| 94761 | <1% | 319 | $56.96 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 83 | $55.50 |
| 85049 | <1% | 55 | $53.61 | |
| 84132 | <1% | 28 | $36.77 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,162 | $19.79 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,372 | $15.98 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,833 | $15.01 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 1,432 | $13.77 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | <1% | 75 | $0.35 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 27 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 574 | $0.00 |
| A4351 | Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, or silicone elastomer, etc.), each | 0% | 29 | $0.00 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 27 | $0.00 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 31 | $0.00 |
| Q0247 | Injection, sotrovimab, 500 mg | 0% | 20 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 16 | $0.00 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 0% | 468 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 448 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 239 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 12 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 28 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDINGER, BRAD (CFO)
| Provider | Location | Paid |
|---|---|---|
| UPMC Northwest | Seneca, PA | $5.33M |
| UPMC Kane | Kane, PA | $1.09M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.